Teva Pharmaceutical Industries said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with American biotechnology company Amgen over its generic Cinacalcet HCl product.
Cinacalcet is a calcium-sensing receptor agonist indicated for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis. It is also used for the treatment of hypercalcemia in adult patients with parathyroid carcinoma and severe hypercalcemia in adult patients with primary HPT who are unable to undergo a parathyroidectomy.
The Israel-based drugmaker has also agreed to stop selling its generic product until its license date expires in mid-2021, or earlier under certain circumstances.
Teva will pay Amgen an undisclosed amount as part of the settlement. That amount and other terms of the settlement remain confidential.
Teva said it recently received approval for the generic product and launched it in the United States.
